Related Experiment Video

Updated: May 5, 2026

Intubation-mediated Intratracheal IMIT Instillation: A Noninvasive, Lung-specific Delivery System
08:00

Intubation-mediated Intratracheal IMIT Instillation: A Noninvasive, Lung-specific Delivery System

Published on: November 17, 2014

26.9K

Inhaled antibiotics to treat lung infection

David Cipolla1, Hak-Kim Chan

  • 1Department of Pharmacy, Pharmacy & Bank Building A15, The University of Sydney, NSW, 2006, Australia.

Pharmaceutical Patent Analyst
|November 19, 2013
PubMed

Insights

This review analyzes patent coverage for inhaled antibiotics, focusing on treatments for lung infections like those in cystic fibrosis. It highlights the competitive landscape of approved and developing inhaled antibiotic products.

Area of Science:

  • Pharmacology
  • Intellectual Property Law
  • Respiratory Medicine

Background:

  • Inhaled antibiotics are crucial for treating lung infections, especially in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.
  • The market features approved products like TOBI® tobramycin and Cayston® aztreonam, with newer formulations such as Bethkis® and TOBI Podhaler® increasing competition.

Purpose of the Study:

  • To address the lack of comprehensive reviews on the patent coverage of currently approved and developing inhaled antibiotic products.
  • To provide a detailed overview of the intellectual property landscape surrounding inhaled antibiotic therapies.

Main Methods:

  • Systematic review of patent literature related to inhaled antibiotic formulations and delivery devices.
  • Analysis of patent filings and granted patents for key inhaled antibiotic products.

Main Results:

  • Identification of key patents covering tobramycin and aztreonam formulations for inhalation.
  • Mapping of patent exclusivity periods and potential market entry for generic competitors.
  • Overview of patent strategies employed by pharmaceutical companies in the inhaled antibiotic space.

Conclusions:

  • Understanding patent coverage is essential for navigating the competitive inhaled antibiotic market.
  • The patent landscape reveals significant intellectual property protection for existing therapies, influencing future development and market access.
  • This review provides valuable insights for researchers, clinicians, and industry stakeholders involved in inhaled antibiotic development and commercialization.

More Related Videos

Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation09:56

Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation

Published on: March 2, 2016

10.0K
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

10.6K

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
58